Biomimetic metal-drug coordination nanoplatform to counteract drug resistance in Pseudomonas aeruginosa via energy disruption

The rapid emergence of antimicrobial resistance is a critical global health challenge that renders conventional antibiotics ineffective. Developing innovative strategies to resensitize drug-resistant pathogens to existing antibiotics represents a promising therapeutic approach. Here, we present a biomimetic nanoplatform (Ce-Car@EV NPs) through the rational integration of ginger-derived extracellular vesicles (EVs) and a pH-responsive cerium-carbenicillin coordination nanoparticles (Ce-Car NCPs). This design enables prolonged circulation and targeted degradation in acidic infection sites, releasing Ce<sup>4+</sup> ions and carbenicillin. The released Ce<sup>4+</sup> ions penetrate the bacterial cells, where they disrupt ATP synthesis, impede oxidative phosphorylation, and inhibit the activity of efflux pump. By depleting ATP, blocking efflux pumps, and thereby reversing bacterial resistance, Ce<sup>4+</sup> ions act as a potent adjuvant to carbenicillin. Here we show that this strategy effectively restores carbenicillin efficacy against drug-resistant Pseudomonas aeruginosa both in vitro and in vivo, establishing a therapeutic strategy leveraging metallic adjuvants to counteract antimicrobial resistance.

Authors

Institutions

Publication Details

Journal
Nature Communications
Published
2026-02-15
DOI
https://doi.org/10.1038/s41467-026-69712-6
Primary Topic
Nanoplatforms for cancer theranostics
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Biomimetic metal-drug coordination nanoplatform to counteract drug resistance in Pseudomonas aeruginosa via energy disruption

Yingmin Ye, Fu‐Jian Xu, Yang Li, Yanmin Wang et al.
Nature Communications
Nanoplatforms for cancer theranostics
article

Biomimetic metal-drug coordination nanoplatform to counteract drug resistance in Pseudomonas aeruginosa via energy disruption

Yingmin Ye, Fu‐Jian Xu, Yang Li, Yanmin Wang, Nana Zhao, Kai Zhang
article en

Abstract

The rapid emergence of antimicrobial resistance is a critical global health challenge that renders conventional antibiotics ineffective. Developing innovative strategies to resensitize drug-resistant pathogens to existing antibiotics represents a promising therapeutic approach. Here, we present a biomimetic nanoplatform (Ce-Car@EV NPs) through the rational integration of ginger-derived extracellular vesicles (EVs) and a pH-responsive cerium-carbenicillin coordination nanoparticles (Ce-Car NCPs). This design enables prolonged circulation and targeted degradation in acidic infection sites, releasing Ce<sup>4+</sup> ions and carbenicillin. The released Ce<sup>4+</sup> ions penetrate the bacterial cells, where they disrupt ATP synthesis, impede oxidative phosphorylation, and inhibit the activity of efflux pump. By depleting ATP, blocking efflux pumps, and thereby reversing bacterial resistance, Ce<sup>4+</sup> ions act as a potent adjuvant to carbenicillin. Here we show that this strategy effectively restores carbenicillin efficacy against drug-resistant Pseudomonas aeruginosa both in vitro and in vivo, establishing a therapeutic strategy leveraging metallic adjuvants to counteract antimicrobial resistance.

Nature CommunicationsVol. 17(1)
Beijing University of Technology (CN), Quzhou University (CN), Beijing University of Chemical Technology (CN)
National Natural Science Foundation of China
Openalex Percentile: Top 55%
Nanoplatforms for cancer theranostics
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.